Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus GP induction chemotherapy and IMRT versus GP induction chemotherapy and IMRT in locally advanced nasopharyngeal carcinoma
ChiCTR2500101638Phase 3Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Apr 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of camrelizumab in nasopharyngeal carcinoma (NPC) (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoint: event-free survival. Started Apr 2025; status: recruiting.
02
Drugs
camrelizumab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR2500101638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500101638.